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TABLE 1 Comparison of Outcomes at 6 Months Based on BMI
Ambulatory Blood
Pressure, mm Hg Denervation Sham p Value
BMI >38 kg/m2 n ¼ 87 n ¼ 30
SBP 8.20  15.93 9.79  15.91 0.64
DBP 5.13  9.50 6.05  9.92 0.65
BMI $30 to #38 kg/m2 n ¼ 151 n ¼ 86
SBP 6.56  15.41 3.28  18.91 0.17
DBP 3.94  9.73 2.58  10.77 0.32
BMI <30 kg/m2 n ¼ 87 n ¼ 42
SBP 5.64  13.73 4.50  14.20 0.66
DBP 3.34  7.95 2.06  8.67 0.41
BMI >27 to <30 kg/m2 n ¼ 42 n ¼ 23
SBP 2.13  14.63 3.22  14.79 0.78
DBP 2.42  8.58 1.24  8.97 0.60
Values are mean  SD.
BMI ¼ body mass index; DBP ¼ diastolic blood pressure; SBP ¼ systolic blood
pressure.
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960sham groups (Table 1). We did observe a smaller,
albeit nonsigniﬁcant, fall in ambulatory blood pres-
sure among lean compared with obese subjects in
both treatment groups.
The adipocyte produces aldosterone, so we inves-
tigated the effect of spironolactone according to BMI
(3). Spironolactone use produced no signiﬁcant dif-
ferences in ambulatory blood pressure endpoints be-
tween obese and normal weight patients. Moreover,
among the denervation subgroup receiving spi-
ronolactone at baseline, there was no difference in
blood pressure change between the obese (n ¼ 26;
BMI >38 kg/m2) and the lean (n ¼ 21; BMI <30 kg/m2)
patients (8.3  12.5 mm Hg vs. 10.4  13.7 mm Hg;
p ¼ 0.59). Additionally, spironolactone in obese sham
subjects (n ¼ 14) failed to provide a signiﬁcant drop in
blood pressure compared with lean sham subjects
receiving spironolactone (n ¼ 8; 9.4  15.7 mm Hg
vs. 0.3  19.5 mm Hg; p ¼ 0.22).
Given the overall neutral results of SYMPLICITY
HTN-3 (4,5), it is difﬁcult to draw any meaningful
conclusions from these data. Additional post-hoc
analysis of SYMPLICITY HTN-3 data by our group
have proposed several potential factors, including
those involving procedural factors, medication
adherence, and patient subgroups. These analyses
further highlight the importance of well-designed,
randomized, sham-controlled clinical trials to clarify
our understanding of the potential role for renal
denervation in the management of uncontrolled hy-
pertension in obese and lean patients.*George L. Bakris, MD
Deepak L. Bhatt, MD, MPH*ASH Comprehensive Hypertension Center
The University of Chicago Medicine
5841 South Maryland Avenue
MC 1027
Chicago, Illinois 60637
E-mail: gbakris@medicine.bsd.uchicago.edu
http://dx.doi.org/10.1016/j.jacc.2014.11.058
Please note: Dr. Bakris has received consultant fees from Takeda, AbbVie,
Novartis, Janssen, BMS, Bayer, Medtronic, Relypsa, Orexigen, Merck, and
GSK; and has grant funding of an investigator-initiated grant from Takeda; is
the editor of the American Journal of Nephrology and Hypertension section of
UpToDate; and is associate editor of Diabetes Care and section editor of
Nephrology, Dialysis and Transplant. Dr. Bhatt is on Advisory Boards for
Elsevier Practice Update Cardiology, Medscape Cardiology, and Regado Bio-
sciences; is on the Board of Directors for Boston VA Research Institute and
Society of Cardiovascular Patient Care; is chair of the American Heart As-
sociation Get With The Guidelines Steering Committee; is on Data Moni-
toring Committees for Duke Clinical Research Institute, Harvard Clinical
Research Institute, Mayo Clinic, and Population Health Research Institute
(including for EnligHTNment); and receives honoraria from the American
College of Cardiology (editor, Clinical Trials, Cardiosource), Belvoir Publica-
tions (Editor in Chief, Harvard Heart Letter), Duke Clinical Research Institute
(clinical trial steering committees), Harvard Clinical Research Institute (clin-
ical trial steering committee), HMP Communications (editor in chief, Journal
of Invasive Cardiology), Population Health Research Institute (clinical trial
steering committee), Slack Publications (chief medical editor, Cardiology
Today’s Intervention), WebMD (CME steering committees), Clinical Cardiology
(associate editor), Journal of the American College of Cardiology (section
editor, Pharmacology); has received research grants from Amarin, Astra-
Zeneca, Bristol-Myers Squibb, Eisai, Ethicon, Medtronic (as co-principal
investigator of SYMPLICITY HTN-3), Roche, Sanoﬁ, and The Medicines
Company; and has performed unfunded research for FlowCo, PLx Pharma,
and Takeda.
R EF E RENCE S
1. Esler M, Straznicky N, Eikelis N, Masuo K, Lambert G, Lambert E. Mecha-
nisms of sympathetic activation in obesity-related hypertension. Hypertension
2006;48:787–96.
2. Lambert E, Straznicky N, Schlaich M, et al. Differing pattern of sym-
pathoexcitation in normal-weight and obesity-related hypertension. Hyper-
tension 2007;50:862–8.
3. Schinner S, Willenberg HS, Krause D, et al. Adipocyte-derived products
induce the transcription of the StAR promoter and stimulate aldosterone and
cortisol secretion from adrenocortical cells through the Wnt-signaling
pathway. Int J Obes (Lond) 2007;31:864–70.
4. Bhatt DL, Kandzari DE, O’Neill WW, et al. A controlled trial of renal
denervation for resistant hypertension. New Engl J Med 2014;370:1393–401.
5. Bakris GL, Townsend RR, Liu M, et al. Impact of renal denervation on
24-hour ambulatory blood pressure: results from SYMPLICITY HTN-3. J Am
Coll Cardiol 2014;64:1071–8.Aspiration Thrombectomy
Timing Should Be ConsideredWe read the recent report by Thiele et al. (1) with
great interest. The investigators performed a multi-
center, randomized trial to compare the adjunctive
aspiration thrombectomy (AT) with conventional
percutaneous coronary intervention (PCI) in patients
with non–ST-segment elevation myocardial in-
farction (NSTEMI). Patients presented within 72 h
after symptom onset and with thrombus over culprit
lesion demonstrated by angiography were enrolled.
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961Although 75% of patients in the AT group yielded
macroscopic thrombus material, the associated
microvascular obstruction assessed by magnetic
resonance imaging within 4 days was not different
from that of the control. The investigators conclude
that adjunctive AT does not lead to an improvement
of myocardial reperfusion and infarct size in patients
with NSTEMI. This conclusion, however, is arguable
because an important confounding factor was left out
from the analysis, namely the time from symptom
onset to PCI.
In the report from Thiele et al. (1), the time from
symptom onset to PCI was extended to 72 h, much
longer than the time limit used in previous AT trials
(<12 h in most AT trials in STEMI, and <24 h in the
earliest trial proving feasibility of AT in NSTEMI [2]).
The duration from symptom onset to PCI is associated
with the change in composition of thrombus material
(3). As thrombi “age,” the proportion of fresh throm-
botic material decreases whereas organized material
increases. Therefore, the effectiveness of AT in
restoring brisk coronary ﬂow will be reduced if done
late. In addition, irreversible injury also progresses in
the jeopardized, but salvageable, myocardium as
critical ischemia continues. This timing difference in
the effect of AT on myocardial reperfusion in STEMI
patients has been shown in previous studies (4,5). In
our previous study, the beneﬁt of AT is most signiﬁ-
cant in STEMI patients treated within 4 to 8 h after
symptom onset, compared with patients treated
within 0 to 4 h or 8 to 12 h. It is possible that within
4 h from onset the thrombi are so soft that they may
respond similarly to either conventional PCI or AT. On
the other hand, when AT was done later than 8 h from
onset, the thrombi are too organized to be removed
completely. In addition, as there is minimal myocar-
dium left to be salvaged late in the course, the beneﬁt
of AT will be mitigated. The changes in thrombus
composition and loss of salvageable myocardium as
time lapsed may thus result in an optimal “time
window” for AT to be effective. We believe, therefore,
the timing of AT after symptom onset should be
considered and analyzed accordingly in all future AT
studies.Chi-Sheng Hung, MD
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Timing Should Be ConsideredWe thank Dr. Hung and colleagues for their consid-
erations on timing of thrombectomy. In the TATORT-
NSTEMI (Thrombus Aspiration in Thrombus
Containing Culprit Lesions in Non-ST-Elevation
Myocardial Infarction) trial, the inclusion criterion
was indeed last symptoms <72 h, which is longer than
in previous ST-segment elevation myocardial infarc-
tion (STEMI) trials in which primary PCI is usually
performed <12 h after symptom onset, although the
recent TAPAS trial (Thrombus Aspiration during
Percutaneous coronary intervention in Acute
myocardial infarction Study) had a 24-h inclusion
criterion (1,2). However, in non-STEMI (NSTEMI), it is
usually difﬁcult to deﬁne the exact symptom onset
and also the last symptom occurrence because
symptoms are often stuttering. Therefore, the inclu-
sion criterion of last symptoms has been chosen in
multiple previous NSTEMI trials ranging from 24 to
72 h (3). Although the 72 h inclusion criterion in the
TATORT-NSTEMI trial was in the upper range in
comparison to other NSTEMI trials, the time from
last symptoms to angiography (TATORT-NSTEMI:
10.5 h thrombectomy vs. 10.0 h control) was similar
to previous trials ranging from 8 to 10 h in a timing
trial (3) and even shorter in comparison to another
trial with approximately 30 h until invasive angiog-
raphy (4).
Thrombus age may play a role on thrombec-
tomy success in STEMI patients. Currently, there is
conﬂicting evidence that aspiration thrombectomy
